Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448754 · ClinicalTrials.gov registry record · Phase 2
Volrustomig Priming Regimens Exploratory Phase II Platform Study
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT06448754: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AstraZeneca.
NCT06448754 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06448754, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
Primary Outcome
The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Ramucirumab
- DRUG Volrustomig
Study Locations (20)
Other
- Research Site - Beijing
- Research Site - Hangzhou
- Research Site - Jinan
- Research Site - Yantai
- Research Site - Zhengzhou
- Research Site - Bois-Guillaume
- Research Site - Caen
- Research Site - Créteil
- Research Site - Dijon
- Research Site - Montpellier
- Research Site - Batumi
- Research Site - Tbilisi
Colorado
- Research Site - Grand Junction
- Research Site - Wheat Ridge
California
- Research Site - Los Angeles
Maryland
- Research Site - Baltimore
Michigan
- Research Site - Detroit
North Carolina
- Research Site - Chapel Hill
Washington
- Research Site - Tacoma
Quebec
- Research Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2027-07-30 |
| Phase | Phase 2 |
What NCT06448754 shows while recruiting
NCT06448754 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT06448754 names 20 study sites across 8 states, led by Other, Colorado, California.
Frequently Asked Questions
What is clinical trial NCT06448754 about?
NCT06448754 is a clinical study titled "Volrustomig Priming Regimens Exploratory Phase II Platform Study". Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.
What is the current status of trial NCT06448754?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2024-08-27. Estimated completion is 2027-07-30.
What conditions does trial NCT06448754 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06448754?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Ramucirumab (DRUG), Volrustomig (DRUG).
Who is sponsoring clinical trial NCT06448754?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06448754 being conducted?
This trial has 20 study locations across California, Colorado, Maryland, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06448754's enrollment target sits among peer trials
180 175th of 454 higher than 277 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI